The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.

There is only one week remaining to submit your new product to vie for a coveted spot in The Scientist’s 2022 competition.

Canada has ordered 76 million doses of Covifenz, the main ingredient of which was manufactured in the leaves of a tobacco relative.

The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.

The masks contain freeze-dried, cell-free biosensors, enabling them to detect pathogens including SARS-CoV-2.

Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.

Scientifically groundless regulations could undercut the potential of gene-edited crops, much as they have with GMOs.

The decision, which concerns the removal of a sugar molecule on the surface of cells in a line of domestic pigs, marks the first time an approval has been granted for both purposes simultaneously.

Super-resolution imaging identifies abnormalities in the hair-like protrusions on a cell’s surface and may help facilitate earlier detection of primary ciliary dyskinesia.

Three-dimensional polymer matrices offer researchers a new representation of the extracellular matrix that can be used to study the growth of cancer cells.

All six calves inherited the gene for preventing horn growth, but four also got a piece of the plasmid used to introduce the sequence to their dad—complicating regulatory approval.

Researchers are developing a variety of approaches for clearing neural tissue to get a better view of the brain’s circuitry.

Genetic engineers have co-opted base editing machinery to enable information storage and processing in the DNA of bacterial and mammalian cells.

The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.

Submit your new product by the end of the day Monday to have a chance at being selected for a coveted spot in The Scientist's 2019 competition.

Unlike biotech tools adapted from nature, the invention was entirely conceived by humans and represents one of the few proteins made from scratch in the lab.

A new portable instrument could help to lure useful bugs in from the wild.

At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.

The documentary weaves together a hunt for mammoth tusks in the Arctic with scenes from the front lines of synthetic biology.